Generic placeholder image

Current Traditional Medicine

Editor-in-Chief

ISSN (Print): 2215-0838
ISSN (Online): 2215-0846

Systematic Review Article

Effect and Mechanism of Curcumin on Bone Loss and Osteoporosis: A Systematic Review

Author(s): Shahrzad Habibi Ghahfarrokhi, Saeid Heidari-Soureshjani*, Parham Talebi-Boroujeni and Catherine M.T. Sherwin

Volume 9, Issue 6, 2023

Published on: 16 November, 2022

Article ID: e241022210320 Pages: 10

DOI: 10.2174/2215083809666221024090809

Price: $65

Abstract

Background: Curcumin has been used in various diseases due to its potent anti-oxidant and anti-inflammatory properties.

Objective: This systematic review aims to investigate the effect and mechanism of curcumin on bone loss and osteoporosis.

Methods: Those human cell line and clinical trial studies indexed in three databases, including PubMed, Institute for Scientific Information (ISI), and Scopus, were included in the review. Records with non-English language articles, full texts not retrieved, and studies that were not relevant to the purpose of our study were excluded. Finally, after evaluating all available records, 11 articles were included.

Results: Curcumin induces antiosteoporotic properties by inhibiting the overproduction of reactive oxygen species (ROS) and free radical scavenging activity. Curcumin, through blocking nuclear factor kappa B (NF-κB) transmission to the nucleus, can suppress the production pathways of inflammatory cytokine production. Moreover, the biological mechanism of curcumin is a complex process associated with the modulation of transcription factors, protein kinases, and antiapoptotic proteins.

Conclusion: The results of most clinical trials and human cell-based studies support the desirable impact of curcumin on bone loss and osteoporosis. Further clinical studies are needed to derive more reliable results about the prophylactic and therapeutic properties of curcumin on osteoporosis.

Keywords: Curcumin, osteoporosis, bone loss, bone density, Curcuma longa, meta-analysis.

Graphical Abstract
[1]
Salari N, Ghasemi H, Mohammadi L, et al. The global prevalence of osteoporosis in the world: A comprehensive systematic review and meta-analysis. J Orthop Surg Res 2021; 16(1): 609-9.
[http://dx.doi.org/10.1186/s13018-021-02772-0] [PMID: 34657598]
[2]
Gold DT, Williams SA, Weiss RJ, et al. Impact of fractures on quality of life in patients with osteoporosis: A US cross-sectional survey. J Drug Assess 2019; 8(1): 175-83.
[http://dx.doi.org/10.1080/21556660.2019.1677674] [PMID: 31692954]
[3]
Hemmati E, Mirghafourvand M, Mobasseri M, Shakouri SK, Mikaeli P, Farshbaf-Khalili A. Prevalence of primary osteoporosis and low bone mass in postmenopausal women and related risk factors. J Educ Health Promot 2021; 10: 204-4.
[PMID: 34395641]
[4]
Sözen T, Özışık L, Calik Basaran N. An overview and management of osteoporosis. Eur J Rheumatol 2017; 4(1): 46-56.
[http://dx.doi.org/10.5152/eurjrheum.2016.048] [PMID: 28293453]
[5]
Lötters FJB, van den Bergh JP, de Vries F, Rutten-van Mölken MPMH. Current and future incidence and costs of osteoporosis-related fractures in the Netherlands: Combining claims data with BMD measurements. Calcif Tissue Int 2016; 98(3): 235-43.
[http://dx.doi.org/10.1007/s00223-015-0089-z] [PMID: 26746477]
[6]
Kling JM, Clarke BL, Sandhu NP. Osteoporosis prevention, screening, and treatment: A review. J Womens Health 2014; 23(7): 563-72.
[http://dx.doi.org/10.1089/jwh.2013.4611] [PMID: 24766381]
[7]
Kwon HY, Ha YC, Yoo JI. Health-related quality of life in accordance with fracture history and comorbidities in korean patients with osteoporosis. J Bone Metab 2016; 23(4): 199-206.
[http://dx.doi.org/10.11005/jbm.2016.23.4.199] [PMID: 27965941]
[8]
Lems WF, Raterman HG. Critical issues and current challenges in osteoporosis and fracture prevention. An overview of unmet needs. Ther Adv Musculoskelet Dis 2017; 9(12): 299-316.
[http://dx.doi.org/10.1177/1759720X17732562] [PMID: 29201155]
[9]
Vondracek S, Minne P, McDermott MT. Clinical challenges in the management of osteoporosis. Clin Interv Aging 2008; 3(2): 315-29.
[http://dx.doi.org/10.2147/CIA.S2539] [PMID: 18686753]
[10]
Ekor M. The growing use of herbal medicines: Issues relating to adverse reactions and challenges in monitoring safety. Front Pharmacol 2014; 4: 177-7.
[http://dx.doi.org/10.3389/fphar.2013.00177] [PMID: 24454289]
[11]
Bagherniya M, Soleimani D, Rouhani MH, Askari G, Sathyapalan T, Sahebkar A. The use of curcumin for the treatment of renal disorders: A systematic review of randomized controlled trials. Adv Exp Med Biol 2021; 1291: 327-43.
[http://dx.doi.org/10.1007/978-3-030-56153-6_19] [PMID: 34331699]
[12]
Alvarenga L, Salarolli R, Cardozo LFMF, et al. Impact of curcumin supplementation on expression of inflammatory transcription factors in hemodialysis patients: A pilot randomized, double-blind, controlled study. Clin Nutr 2020; 39(12): 3594-600.
[http://dx.doi.org/10.1016/j.clnu.2020.03.007] [PMID: 32204978]
[13]
Li H, Yue L, Xu H, et al. Curcumin suppresses osteogenesis by inducing miR-126a-3p and subsequently suppressing the WNT/LRP6 pathway. Aging 2019; 11(17): 6983-98.
[http://dx.doi.org/10.18632/aging.102232] [PMID: 31480018]
[14]
Cantero-Navarro E, Rayego-Mateos S, Orejudo M, et al. Role of macrophages and related cytokines in kidney disease. Front Med 2021; 8: 688060.
[http://dx.doi.org/10.3389/fmed.2021.688060] [PMID: 34307414]
[15]
Abdolalipour S, Mirghafourvand M, Mobasseri M, et al. Assessment of primary osteoporosis status in the postmenopausal women of tabriz and the effect of curcumin nanomicelles, Nigella sativa Oil, and Curcumin Nanomicelles and Nigella sativa Oil Soft Capsules on Cellular-Molecular and Clinical Outcomes: A Study Protocol. Int J Women’s Health Reprod Sci 2020; 9(1): 003-10.
[http://dx.doi.org/10.15296/ijwhr.2021.02]
[16]
Shi LP, Jian Z, Zhao SP, Wu YW. Curcumin and Risendronate/hydroxyapatite co-loaded lipid-polymer nanoparticle to enhance the therapeutic efficacy in osteoporosis. J Microbiol Biotechnol Res 2016; 11: 1-7.
[17]
Chang R, Sun L, Webster TJ. Short communication: selective cytotoxicity of curcumin on osteosarcoma cells compared to healthy osteoblasts. Int J Nanomedicine 2014; 9: 461-5.
[PMID: 24453488]
[18]
Carnovali M, Ramoni G, Banfi G, Mariotti M. Herbal Preparation (Bromelain, Papain, Curcuma, Black Pepper) enhances mineralization and reduces glucocorticoid-induced osteoporosis in zebrafish. Antioxidants 2021; 10(12): 1987.
[http://dx.doi.org/10.3390/antiox10121987] [PMID: 34943090]
[19]
Sutjarit N, Thongon N, Weerachayaphorn J, et al. Inhibition of adipogenic differentiation of human bone marrow-derived mesenchymal stem cells by a phytoestrogen diarylheptanoid from Curcuma comosa. J Agric Food Chem 2020; 68(37): 9993-10002.
[http://dx.doi.org/10.1021/acs.jafc.0c04063] [PMID: 32838526]
[20]
Aghamohammadi D, Dolatkhah N, Shakouri SK, Hermann P, Eslamian F. Ginger (Zingiber officinale) and turmeric (Curcuma longa L.) supplementation effects on quality of life, body composition, bone mineral density and osteoporosis related biomarkers and micro-RNAs in women with postmenopausal osteoporosis: a study protocol for a randomized controlled clinical trial. J Complement Integr Med 2021; 18(1): 131-7.
[http://dx.doi.org/10.1515/jcim-2020-0017] [PMID: 32568732]
[21]
Mawani Y, Orvig C. Improved separation of the curcuminoids, syntheses of their rare earth complexes, and studies of potential antiosteoporotic activity. J Inorg Biochem 2014; 132: 52-8.
[http://dx.doi.org/10.1016/j.jinorgbio.2013.12.004] [PMID: 24387940]
[22]
Riva A, Togni S, Giacomelli L, et al. Effects of a curcumin-based supplementation in asymptomatic subjects with low bone density: a preliminary 24-week supplement study. Eur Rev Med Pharmacol Sci 2017; 21(7): 1684-9.
[PMID: 28429336]
[23]
Hatefi M, Ahmadi MRH, Rahmani A, Dastjerdi MM, Asadollahi K. Effects of curcumin on bone loss and biochemical markers of bone turnover in patients with spinal cord injury. World Neurosurg 2018; 114: e785-91.
[http://dx.doi.org/10.1016/j.wneu.2018.03.081] [PMID: 29567290]
[24]
Khanizadeh F, Rahmani A, Asadollahi K, Ahmadi MRH. Combination therapy of curcumin and alendronate modulates bone turnover markers and enhances bone mineral density in postmenopausal women with osteoporosis. Arch Endocrinol Metab 2018; 62(4): 438-45.
[http://dx.doi.org/10.20945/2359-3997000000060] [PMID: 30304108]
[25]
Murillo Ortiz BO, Fuentes Preciado AR. Ramírez Emiliano J, Martínez Garza S, Ramos Rodríguez E, de Alba Macías LA. Recovery of bone and muscle mass in patients with chronic kidney disease and iron overload on hemodialysis and taking combined supplementation with curcumin and resveratrol. Clin Interv Aging 2019; 14: 2055-62.
[http://dx.doi.org/10.2147/CIA.S223805] [PMID: 31819387]
[26]
Farshbaf-Khalili A, Farajnia S, Pourzeinali S, Shakouri SK, Salehi-Pourmehr H. The effect of nanomicelle curcumin supplementation and Nigella sativa oil on the expression level of miRNA ‐21, miRNA ‐422a, and miRNA ‐503 gene in postmenopausal women with low bone mass density: A randomized, triple‐blind, placebo‐controlled clinical trial with factorial design. Phytother Res 2021; 35(11): 6216-27.
[http://dx.doi.org/10.1002/ptr.7259] [PMID: 34496087]
[27]
Kheiridoost H, Shakouri SK, Shojaei-Zarghani S, Dolatkhah N, Farshbaf-Khalili A. Efficacy of nanomicelle curcumin, Nigella sativa oil, and their combination on bone turnover markers and their safety in postmenopausal women with primary osteoporosis and osteopenia: A triple‐blind randomized controlled trial. Food Sci Nutr 2022; 10(2): 515-24.
[http://dx.doi.org/10.1002/fsn3.2674] [PMID: 35154688]
[28]
Chan WH, Wu HY, Chang WH. Dosage effects of curcumin on cell death types in a human osteoblast cell line. Food Chem Toxicol 2006; 44(8): 1362-71.
[http://dx.doi.org/10.1016/j.fct.2006.03.001] [PMID: 16624471]
[29]
Moran J, Roncero-Martin R, Rodriguez-Velasco F, et al. Effects of curcumin on the proliferation and mineralization of human osteoblast-like cells: implications of nitric oxide. Int J Mol Sci 2012; 13(12): 16104-18.
[http://dx.doi.org/10.3390/ijms131216104] [PMID: 23443113]
[30]
Wang N, Wang F, Gao Y, et al. Curcumin protects human adipose-derived mesenchymal stem cells against oxidative stress-induced inhibition of osteogenesis. J Pharmacol Sci 2016; 132(3): 192-200.
[http://dx.doi.org/10.1016/j.jphs.2016.10.005] [PMID: 27840063]
[31]
Dai P, Mao Y, Sun X, et al. Attenuation of oxidative stress-induced osteoblast apoptosis by curcumin is associated with preservation of mitochondrial functions and increased Akt-GSK3β signaling. Cell Physiol Biochem 2017; 41(2): 661-77.
[http://dx.doi.org/10.1159/000457945] [PMID: 28291961]
[32]
Stohs SJ, Chen O, Ray SD, Ji J, Bucci LR, Preuss HG. Highly bioavailable forms of curcumin and promising avenues for curcumin-based research and application: a review. Molecules 2020; 25(6): 1397.
[http://dx.doi.org/10.3390/molecules25061397] [PMID: 32204372]
[33]
Prasad S, DuBourdieu D, Srivastava A, Kumar P, Lall R. Metal–curcumin complexes in therapeutics: An approach to enhance pharmacological effects of curcumin. Int J Mol Sci 2021; 22(13): 7094.
[http://dx.doi.org/10.3390/ijms22137094] [PMID: 34209461]
[34]
Seeman E. Bone quality: The material and structural basis of bone strength. J Bone Miner Metab 2008; 26(1): 1-8.
[http://dx.doi.org/10.1007/s00774-007-0793-5] [PMID: 18095057]
[35]
Muthusami S, Ramachandran I, Muthusamy B, et al. Ovariectomy induces oxidative stress and impairs bone antioxidant system in adult rats. Clin Chim Acta 2005; 360(1-2): 81-6.
[http://dx.doi.org/10.1016/j.cccn.2005.04.014] [PMID: 15970279]
[36]
Baek KH, Oh KW, Lee WY, et al. Association of oxidative stress with postmenopausal osteoporosis and the effects of hydrogen peroxide on osteoclast formation in human bone marrow cell cultures. Calcif Tissue Int 2010; 87(3): 226-35.
[http://dx.doi.org/10.1007/s00223-010-9393-9] [PMID: 20614110]
[37]
Domazetovic V, Marcucci G, Iantomasi T, Brandi ML, Vincenzini MT. Oxidative stress in bone remodeling: Role of antioxidants. Clin Cases Miner Bone Metab 2017; 14(2): 209-16.
[http://dx.doi.org/10.11138/ccmbm/2017.14.1.209] [PMID: 29263736]
[38]
Manolagas SC. From estrogen-centric to aging and oxidative stress: a revised perspective of the pathogenesis of osteoporosis. Endocr Rev 2010; 31(3): 266-300.
[http://dx.doi.org/10.1210/er.2009-0024] [PMID: 20051526]
[39]
Tsay J, Yang Z, Ross FP, et al. Bone loss caused by iron overload in a murine model: Importance of oxidative stress. Blood 2010; 116(14): 2582-9.
[http://dx.doi.org/10.1182/blood-2009-12-260083] [PMID: 20554970]
[40]
Lean JM, Jagger CJ, Kirstein B, Fuller K, Chambers TJ. Hydrogen peroxide is essential for estrogen-deficiency bone loss and osteoclast formation. Endocrinology 2005; 146(2): 728-35.
[http://dx.doi.org/10.1210/en.2004-1021] [PMID: 15528306]
[41]
Sahebkar A, Serban MC, Ursoniu S, Banach M. Effect of curcuminoids on oxidative stress: A systematic review and meta-analysis of randomized controlled trials. J Funct Foods 2015; 18: 898-909.
[http://dx.doi.org/10.1016/j.jff.2015.01.005]
[42]
de Almeida Alvarenga L, Leal VO, Borges NA, et al. Curcumin-a promising nutritional strategy for chronic kidney disease patients. J Funct Foods 2018; 40: 715-21.
[http://dx.doi.org/10.1016/j.jff.2017.12.015]
[43]
Cardozo LFMF, Pedruzzi LM, Stenvinkel P, et al. Nutritional strategies to modulate inflammation and oxidative stress pathways via activation of the master antioxidant switch Nrf2. Biochimie 2013; 95(8): 1525-33.
[http://dx.doi.org/10.1016/j.biochi.2013.04.012] [PMID: 23643732]
[44]
Yang C, Zhu K, Yuan X, Zhang X, Qian Y, Cheng T. Curcumin has immunomodulatory effects on RANKL‐stimulated osteoclastogenesis in vitro and titanium nanoparticle‐induced bone loss in vivo. J Cell Mol Med 2020; 24(2): 1553-67.
[http://dx.doi.org/10.1111/jcmm.14842] [PMID: 31845532]
[45]
Krum SA, Chang J, Miranda-Carboni G, Wang CY. Novel functions for NFκB: Inhibition of bone formation. Nat Rev Rheumatol 2010; 6(10): 607-11.
[http://dx.doi.org/10.1038/nrrheum.2010.133] [PMID: 20703218]
[46]
Liu ZJ, Liu HQ, Xiao C, et al. Curcumin protects neurons against oxygen-glucose deprivation/reoxygenation-induced injury through activation of peroxisome proliferator-activated receptor-γ function. J Neurosci Res 2014; 92(11): 1549-59.
[http://dx.doi.org/10.1002/jnr.23438] [PMID: 24975470]
[47]
Rahimi HR, Mohammadpour AH, Dastani M, et al. The effect of nano-curcumin on HbA1c, fasting blood glucose, and lipid profile in diabetic subjects: A randomized clinical trial. Avicenna J Phytomed 2016; 6(5): 567-77.
[PMID: 27761427]
[48]
Pfeilschifter J. Köditz R, Pfohl M, Schatz H. Changes in proinflammatory cytokine activity after menopause. Endocr Rev 2002; 23(1): 90-119.
[http://dx.doi.org/10.1210/edrv.23.1.0456] [PMID: 11844745]
[49]
Krum SA, Miranda-Carboni GA, Hauschka PV, et al. Estrogen protects bone by inducing Fas ligand in osteoblasts to regulate osteoclast survival. EMBO J 2008; 27(3): 535-45.
[http://dx.doi.org/10.1038/sj.emboj.7601984] [PMID: 18219273]
[50]
Gilbert L, He X, Farmer P, et al. Expression of the osteoblast differentiation factor RUNX2 (Cbfa1/AML3/Pebp2α A) is inhibited by tumor necrosis factor-α. J Biol Chem 2002; 277(4): 2695-701.
[http://dx.doi.org/10.1074/jbc.M106339200] [PMID: 11723115]
[51]
Kaneki H, Guo R, Chen D, et al. Tumor necrosis factor promotes Runx2 degradation through up-regulation of Smurf1 and Smurf2 in osteoblasts. J Biol Chem 2006; 281(7): 4326-33.
[http://dx.doi.org/10.1074/jbc.M509430200] [PMID: 16373342]
[52]
Lu X, Gilbert L, He X, Rubin J, Nanes MS. Transcriptional regulation of the osterix (Osx, Sp7) promoter by tumor necrosis factor identifies disparate effects of mitogen-activated protein kinase and NF κ B pathways. J Biol Chem 2006; 281(10): 6297-306.
[http://dx.doi.org/10.1074/jbc.M507804200] [PMID: 16410254]
[53]
Ding J, Ghali O, Lencel P, et al. TNF-α and IL-1β inhibit RUNX2 and collagen expression but increase alkaline phosphatase activity and mineralization in human mesenchymal stem cells. Life Sci 2009; 84(15-16): 499-504.
[http://dx.doi.org/10.1016/j.lfs.2009.01.013] [PMID: 19302812]
[54]
Gilbert LC, Rubin J, Nanes MS. The p55 TNF receptor mediates TNF inhibition of osteoblast differentiation independently of apoptosis. Am J Physiol Endocrinol Metab 2005; 288(5): E1011-8.
[http://dx.doi.org/10.1152/ajpendo.00534.2004] [PMID: 15625085]
[55]
Kitazawa R, Kimble RB, Vannice JL, Kung VT, Pacifici R. Interleukin-1 receptor antagonist and tumor necrosis factor binding protein decrease osteoclast formation and bone resorption in ovariectomized mice. J Clin Invest 1994; 94(6): 2397-406.
[http://dx.doi.org/10.1172/JCI117606] [PMID: 7989596]
[56]
Weitzmann MN, Roggia C, Toraldo G, Weitzmann L, Pacifici R. Increased production of IL-7 uncouples bone formation from bone resorption during estrogen deficiency. J Clin Invest 2002; 110(11): 1643-50.
[http://dx.doi.org/10.1172/JCI0215687] [PMID: 12464669]
[57]
Anderson DM, Maraskovsky E, Billingsley WL, et al. A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function. Nature 1997; 390(6656): 175-9.
[http://dx.doi.org/10.1038/36593] [PMID: 9367155]
[58]
Choi HJ, Park YR, Nepal M, et al. Inhibition of osteoclastogenic differentiation by Ikarisoside A in RAW 264.7 cells via JNK and NF-κB signaling pathways. Eur J Pharmacol 2010; 636(1-3): 28-35.
[http://dx.doi.org/10.1016/j.ejphar.2010.03.023] [PMID: 20353769]
[59]
Ogasawara T, Katagiri M, Yamamoto A, et al. Osteoclast differentiation by RANKL requires NF-kappaB-mediated downregulation of cyclin-dependent kinase 6 (Cdk6). J Bone Miner Res 2004; 19(7): 1128-36.
[http://dx.doi.org/10.1359/jbmr.2004.19.7.1128] [PMID: 15176996]
[60]
Helfrich MH, Thesingh CW, Mieremet RHP, van Iperen-van Gent AS. Osteoclast generation from human fetal bone marrow in cocultures with murine fetal long bones. Cell Tissue Res 1987; 249(1): 125-36.
[http://dx.doi.org/10.1007/BF00215426] [PMID: 3621288]
[61]
Pietschmann P, Mechtcheriakova D, Meshcheryakova A. Föger-Samwald U, Ellinger I. Immunology of osteoporosis: A mini-review. Gerontology 2016; 62(2): 128-37.
[http://dx.doi.org/10.1159/000431091] [PMID: 26088283]
[62]
Bharti AC, Takada Y, Aggarwal BB. Curcumin (diferuloylmethane) inhibits receptor activator of NF-κ B ligand-induced NF-κ B activation in osteoclast precursors and suppresses osteoclastogenesis. J Immunol 2004; 172(10): 5940-7.
[http://dx.doi.org/10.4049/jimmunol.172.10.5940] [PMID: 15128775]
[63]
Kim WK, Ke K, Sul OJ, et al. Curcumin protects against ovariectomy-induced bone loss and decreases osteoclastogenesis. J Cell Biochem 2011; 112(11): 3159-66.
[http://dx.doi.org/10.1002/jcb.23242] [PMID: 21732406]
[64]
Rohanizadeh R, Deng Y, Verron E. Therapeutic actions of curcumin in bone disorders. Bonekey Rep 2016; 5: 793.
[http://dx.doi.org/10.1038/bonekey.2016.20] [PMID: 26962450]
[65]
Zhao R, Yang B, Wang L, et al. Curcumin protects human keratinocytes against inorganic arsenite-induced acute cytotoxicity through an NRF2-dependent mechanism. Oxid Med Cell Longev 2013; 2013: 412576.
[http://dx.doi.org/10.1155/2013/412576]
[66]
Li L, Aggarwal BB, Shishodia S, Abbruzzese J, Kurzrock R. Nuclear factor-?B and I?B kinase are constitutively active in human pancreatic cells, and their down-regulation by curcumin (diferuloylmethane) is associated with the suppression of proliferation and the induction of apoptosis. Cancer 2004; 101(10): 2351-62.
[http://dx.doi.org/10.1002/cncr.20605] [PMID: 15476283]
[67]
Shehzad A, Qureshi M, Anwar MN, Lee YS. Multifunctional curcumin mediate multitherapeutic effects. J Food Sci 2017; 82(9): 2006-15.
[http://dx.doi.org/10.1111/1750-3841.13793] [PMID: 28771714]
[68]
Liu Z, Bao X, Jia S, Hu Y. Constructing the screening cell model of PPARγ and to validate whether the curcumin is the natural agonist of PPARγ. J Apoplexy Nervous Dis 2011; 28: 872-4.
[69]
Liu ZJ, Liu W, Liu L, Xiao C, Wang Y, Jiao JS. Curcumin protects neuron against cerebral ischemia-induced inflammation through improving PPAR-gamma function. Evid Based Complementary Altern Med 2013.
[http://dx.doi.org/10.1155/2013/470975]
[70]
Marie PJ, Kassem M. Osteoblasts in osteoporosis: Past, emerging, and future anabolic targets. Eur J Endocrinol 2011; 165(1): 1-10.
[http://dx.doi.org/10.1530/EJE-11-0132] [PMID: 21543379]
[71]
Chen F, Wang H, Xiang X, et al. Curcumin increased the differentiation rate of neurons in neural stem cells via wnt signaling in vitro study. J Surg Res 2014; 192(2): 298-304.
[http://dx.doi.org/10.1016/j.jss.2014.06.026] [PMID: 25033705]
[72]
Chen Z, Xue J, Shen T, Mu S, Fu Q. Curcumin alleviates glucocorticoid-induced osteoporosis through the regulation of the Wnt signaling pathway. Int J Mol Med 2016; 37(2): 329-38.
[http://dx.doi.org/10.3892/ijmm.2015.2432] [PMID: 26677102]
[73]
Ahn J, Lee H, Kim S, Ha T. Curcumin-induced suppression of adipogenic differentiation is accompanied by activation of Wnt/β-catenin signaling. Am J Physiol Cell Physiol 2010; 298(6): C1510-6.
[http://dx.doi.org/10.1152/ajpcell.00369.2009] [PMID: 20357182]
[74]
Recker RR, Benson CT, Matsumoto T, et al. A randomized, double-blind phase 2 clinical trial of blosozumab, a sclerostin antibody, in postmenopausal women with low bone mineral density. J Bone Miner Res 2015; 30(2): 216-24.
[http://dx.doi.org/10.1002/jbmr.2351] [PMID: 25196993]
[75]
MacDonald BT, Tamai K, He X. Wnt/β-catenin signaling: Components, mechanisms, and diseases. Dev Cell 2009; 17(1): 9-26.
[http://dx.doi.org/10.1016/j.devcel.2009.06.016] [PMID: 19619488]
[76]
Son HE, Kim EJ, Jang WG. Curcumin induces osteoblast differentiation through mild-endoplasmic reticulum stress-mediated such as BMP2 on osteoblast cells. Life Sci 2018; 193: 34-9.
[http://dx.doi.org/10.1016/j.lfs.2017.12.008] [PMID: 29223538]
[77]
Yang Y, Yujiao W, Fang W, et al. The roles of miRNA, lncRNA and circRNA in the development of osteoporosis. Biol Res 2020; 53(1): 40.
[http://dx.doi.org/10.1186/s40659-020-00309-z] [PMID: 32938500]
[78]
Li G, Bu J, Zhu Y, Xiao X, Liang Z, Zhang R. Curcumin improves bone microarchitecture in glucocorticoid-induced secondary osteoporosis mice through the activation of microRNA-365 via regulating MMP-9. Int J Clin Exp Pathol 2015; 8(12): 15684-95.
[PMID: 26884838]
[79]
Meng YB, Li X, Li ZY, et al. microRNA-21 promotes osteogenic differentiation of mesenchymal stem cells by the PI3K/β-catenin pathway. J Orthop Res 2015; 33(7): 957-64.
[http://dx.doi.org/10.1002/jor.22884] [PMID: 25728838]
[80]
Sugatani T, Hruska KA. Down-regulation of miR-21 biogenesis by estrogen action contributes to osteoclastic apoptosis. J Cell Biochem 2013; 114(6): 1217-22.
[http://dx.doi.org/10.1002/jcb.24471] [PMID: 23238785]
[81]
Li H, Wang Z, Fu Q, Zhang J. Plasma miRNA levels correlate with sensitivity to bone mineral density in postmenopausal osteoporosis patients. Biomarkers 2014; 19(7): 553-6.
[http://dx.doi.org/10.3109/1354750X.2014.935957] [PMID: 25231354]
[82]
Yavropoulou MP, Anastasilakis AD, Makras P, Tsalikakis DG, Grammatiki M, Yovos JG. Expression of microRNAs that regulate bone turnover in the serum of postmenopausal women with low bone mass and vertebral fractures. Eur J Endocrinol 2017; 176(2): 169-76.
[http://dx.doi.org/10.1530/EJE-16-0583] [PMID: 27836951]
[83]
Gorabi AM, Kiaie N, Hajighasemi S, Jamialahmadi T, Majeed M, Sahebkar A. The effect of curcumin on the differentiation of mesenchymal stem cells into mesodermal lineage. Molecules 2019; 24(22): 4029.
[http://dx.doi.org/10.3390/molecules24224029] [PMID: 31703322]
[84]
Notoya M, Nishimura H, Woo JT, Nagai K, Ishihara Y, Hagiwara H. Curcumin inhibits the proliferation and mineralization of cultured osteoblasts. Eur J Pharmacol 2006; 534(1-3): 55-62.
[http://dx.doi.org/10.1016/j.ejphar.2006.01.028] [PMID: 16476424]
[85]
Folwarczna J, Zych M, Trzeciak HI. Effects of curcumin on the skeletal system in rats. Pharmacol Rep 2010; 62(5): 900-9.
[http://dx.doi.org/10.1016/S1734-1140(10)70350-9] [PMID: 21098873]
[86]
Blagodatski A, Klimenko A, Jia L, Katanaev VL. Small molecule Wnt pathway modulators from natural sources: History, state of the art and perspectives. Cells 2020; 9(3): 589.
[http://dx.doi.org/10.3390/cells9030589] [PMID: 32131438]
[87]
He M, Li YU, Zhang LI, et al. Curcumin suppresses cell proliferation through inhibition of the Wnt/β-catenin signaling pathway in medulloblastoma. Oncol Rep 2014; 32(1): 173-80.
[http://dx.doi.org/10.3892/or.2014.3206] [PMID: 24858998]
[88]
Cui L, Jia X, Zhou Q, Zhai X, Zhou Y, Zhu H. Curcumin affects β-catenin pathway in hepatic stellate cell in vitro and in vivo. J Pharm Pharmacol 2014; 66(11): 1615-22.
[http://dx.doi.org/10.1111/jphp.12283] [PMID: 24945564]
[89]
Leow PC, Tian Q, Ong ZY, Yang Z, Ee PLR. Antitumor activity of natural compounds, curcumin and PKF118-310, as Wnt/β-catenin antagonists against human osteosarcoma cells. Invest New Drugs 2010; 28(6): 766-82.
[http://dx.doi.org/10.1007/s10637-009-9311-z] [PMID: 19730790]

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy